Issue link: http://osercommunicationsgroup.uberflip.com/i/709458
C h a i n D r u g s t o r e D a i l y 6 3 Tu e s d a y, A u g u s t 9 , 2 0 1 6 2016 Best of Show HIKMA ANNOUNCES FDA APPROVAL, LAUNCH OF FLUTICASONE 50 MCG SPRAY Hikma Pharmaceuticals PLC, the fast growing multinational pharmaceutical group, has announced the approval of Fluticasone 50 MCG Spray, the store brand equivalent of Flonase ® , by the U.S. Food and Drug Administration (FDA). Flonase (fluticasone propionate nasal spray USP, 50 mcg per spray) is indicated for the temporary relief of hay fever or other upper respiratory allergies in adult and pediatric patients four years of age and older. Combined generic and branded sales for the 12 months ending May 2016 were $343 million. Hikma, through its wholly-owned subsidiary West-Ward Pharmaceuticals, has partnered with Perrigo Company PLC, a leading supplier of over-the- counter (OTC) products, for the launch of this product in the OTC market. Perrigo expects to begin customer ship- ments immediately. Michael Raya, Chief Executive of West-Ward Pharmaceuticals, said, "We are very pleased to be working with Perrigo to improve access to this impor- tant product for consumers interested in purchasing fluticasone propionate nasal spray over-the-counter." For inquiries, please contact: Hikma Pharmaceuticals PLC, Susan Ringdal, Vice President Corporate Strategy and Investor Relations at 44.0.20.7399.2760; West-Ward Pharmaceuticals, Keri Butler, Public Affairs and Communications at 614.272.4774; and FTI Consulting, Ben Atwell / Matthew Cole / Julia Phillips at 44.0.20.3727.1000. About Hikma Pharmaceuticals Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufactur- ing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Injectables," "Branded" and "Generics," based principally in the United States, the Middle East and North Africa (MENA) and Europe. Hikma currently employs more than 7,000 staff members world- wide. About West-Ward Pharmaceuticals West-Ward Pharmaceuticals, a wholly- owned subsidiary of Hikma Pharmaceuticals PLC, is a top 10 generic pharmaceutical company in the U.S. focused on providing a broad range of differentiated generic pharmaceutical products across a range of dosage forms. West-Ward has sites in New Jersey, Ohio and Tennessee. About Perrigo Perrigo Company PLC, a top five glob- al over-the-counter con- sumer goods and phar- maceutical company, offers patients and cus- tomers high quality prod- ucts at affordable prices. From its beginnings in 1887 as a packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC products and supplier of infant formulas for the store brand market. The company is also a leading provider of generic extended topical prescription products and receives royalties from Multiple Sclerosis drug Tysabri ® . Perrigo pro- vides Quality Affordable Healthcare Products ® across a wide variety of product categories and geographies, primarily in North America, Europe and Australia, as well as other markets, including Israel, China and Latin America. Visit Perrigo online at www.perrigo.com. For more information, visit booth #2009. ANTHERA PHARMACEUTICALS ANNOUNCES APPOINTMENT OF INTERIM CHIEF MEDICAL OFFICER Anthera Pharmaceuticals, Inc. has announced the appointment of James Pennington, M.D. as interim Chief Medical Officer following the company's acceptance of Colin Hislop's resignation effective April 1st, 2016. "Our development programs have progressed extensively during Colin's tenure at Anthera, and during that time, both blisibimod and Sollpura ® have advanced into late-stage clinical trials. We thank Colin for his contributions to that development progress and wish him much success in his future endeavors," said Craig Thompson, Anthera's President and Chief Operating Officer. "Jim's long history at Anthera and sub- stantial experience with our clinical pro- grams, combined with his successful reg- ulatory and commercialization experi- ence, will continue to play a pivotal role in keeping our development programs on track for achievement of our milestones in 2016." Dr. Pennington assumes the position of interim Chief Medical Officer with more than 40 years of successful clinical development and commercialization, including 14 drug approvals and 10 reg- istration ex-US approvals including both small and large molecule therapeutics. "Working with the dedicated med- ical team at Anthera has been gratifying and I am privileged to lead our develop- ment efforts as interim Chief Medical Officer," said Dr. Pennington. "As we continue the final stages of our clinical programs, I am confident in our team's ability to bring new treatment options to patients with unmet medical needs." Dr. Pennington joined Anthera in 2007 as Executive Vice President and Chief Medical Officer and transitioned to Senior Clinical Fellow in 2010. Prior to joining Anthera in 2007, Dr. Pennington served as Executive Vice President and Chief Medical Officer of CoTherix where he oversaw the approval of Ventavis ® . He previously served as Chief Medical Officer of InterMune as well as in a variety of positions at early stage biotech companies and large global phar- maceutical companies including Alpha Therapeutic Corporation, Shaman Pharmaceuticals and Bayer Corporation. Dr. Pennington spent 12 years as a mem- ber of the Harvard Medical School facul- ty. Dr. Pennington holds a B.A. from the University of Oregon and an M.D. from the University of Oregon Medical School and is Board Certified in internal medi- cine and infectious diseases. For more information, visit www.anthera.com.